CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
“We are excited to utilize NanoString’s world-class nCounter Flex platform to make our advanced genomic tests available to physicians and their patients globally, beginning with our pulmonology products,” Bonnie H. Anderson, chairman and CEO of Veracyte, said in a NanoString press release. “The robust performance and ease of use of the nCounter platform make it ideally suited to expand our market opportunity beyond our CLIA-certified laboratory in the United States.”
Veracyte will pay NanoString $50 million in cash and Veracyte stock plus up to $10 million in cash upon the commercial launch of Veracyte diagnostic tests for use on the nCounter platform.
Pages: 1 2